Curated News
By: NewsRamp Editorial Staff
March 23, 2026

BRAIN Biotech Secures Key Patent for Broad-Spectrum CRISPR Genome Editing Tech

Discuss on LinkedIn Discuss on Telegram
Original Source

TLDR

  • BRAIN Biotech's patented CRISPR-BMC nuclease offers companies a competitive edge by enabling precise, cost-effective strain optimization for industrial biomolecule production.
  • The CRISPR-BMC nuclease creates targeted double-strand breaks in genomes, allowing precise editing across prokaryotic and eukaryotic organisms through BRAIN Biotech's proprietary technology.
  • This technology advances sustainable manufacturing by making microbial production more efficient, potentially reducing costs and environmental impact for essential biomolecules.
  • BRAIN Biotech's newly patented CRISPR system can edit everything from bacteria to mammalian cells, opening new frontiers in genetic engineering.

Impact - Why it Matters

This news matters because it represents a tangible advancement in the democratization and application of CRISPR technology beyond human therapeutics. While much public attention focuses on medical uses, this patent strengthens the toolkit for industrial biotechnology, a field critical to developing more sustainable manufacturing processes. By enabling precise, efficient editing of a wide array of microorganisms—from common workhorses like E. coli and yeast to fungi and plants—this technology can accelerate the development of optimized microbial 'factories.' This has direct implications for producing everything from biofuels and biodegradable plastics to food ingredients and pharmaceuticals in a more efficient, cost-effective, and potentially greener manner. The expansion of licensing activities means this tool could soon be deployed across multiple industries, potentially lowering costs and increasing the scalability of bio-based products, which contributes to a broader transition toward a bioeconomy less reliant on petrochemicals.

Summary

In a significant development for the biotechnology sector, BRAIN Biotech AG has secured robust European patent protection for its novel CRISPR-BMC nuclease family, a proprietary genome-editing technology. The patent, numbered EP4301852 B1 and effective from March 18, 2026, covers a family of nucleases called BMC® (BRAIN Metagenome Cas) that exhibit high activity across a remarkably broad spectrum of organisms. This technology enables precise double-strand breaks in the genomes of both prokaryotic and eukaryotic cells, including bacteria, yeasts, fungi, plants, and mammalian cells, allowing for targeted modifications to optimize microbial production strains for biomolecules like enzymes, proteins, and small molecules.

The company, a leader in specialty enzymes and biological solutions, views this patent as a critical milestone that solidifies its freedom to operate and opens substantial commercial potential through expanded licensing activities. Key executives, including CEO Adriaan Moelker and Head of R&D Alexander Pelzer, emphasize that the CRISPR-BMC technology, developed within the BRAINBioIncubator, complements their existing CRISPR-BEC nucleases and accelerates strain development for customers, aiming to make industrial bioprocesses more cost-effective. The patent is already in force across the European Unitary Patent area, Great Britain, and Switzerland, with applications pending in other key markets like the USA and Japan.

BRAIN Biotech offers this technology through a business model focused on strain optimization for customer production strains, with licenses already granted to companies in various fields. The company's broader operations span two segments: BRAINBiocatalysts for enzyme production and distribution, and the research-intensive BRAINBioIncubator. For more information, stakeholders can visit the company's website at www.brain-biotech-group.com. This advancement underscores BRAIN Biotech's commitment to leveraging decades of molecular biology expertise to deliver innovative, sustainable biological solutions to industry.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, BRAIN Biotech Secures Key Patent for Broad-Spectrum CRISPR Genome Editing Tech

blockchain registration record for this content.